With its vision of “Improving the Future,” Abdi Ibrahim continues its sustainability initiatives, publishing its 7th Sustainability Report covering its activities between January 1, 2023, and December 31, 2023. The report details the company’s long-term projects and sustainability targets for 2030, 2040, and 2050 within the framework of its strategy to improve the future of the ecosystem, people, and business.
Adopting a holistic approach encompassing environmental, social, and governance (ESG) factors, Abdi Ibrahim has made its sustainability report—previously published biennially—an annual publication. As a signatory of the United Nations Global Compact (UNGC) since 2010, the company integrates ten of the UN’s 17 Sustainable Development Goals (SDGs) into its business processes, strategies, and operations. The report includes both qualitative and quantitative data from the company’s headquarters and the Esenyurt Production Complex and adheres to the Global Reporting Initiative (GRI) standards. Additionally, independently verified Scope 1, Scope 2, and Scope 3 greenhouse gas emissions for 2023 are transparently disclosed.
Expanding Impact Through Long-Term Sustainability Projects
As the undisputed leader of the Turkish pharmaceutical sector for 23 consecutive years, Abdi Ibrahim also pioneers sustainability efforts within the industry. By integrating sustainability into all its processes and leveraging science and technology, the company aims to improve the future of the ecosystem, people, and business. Its sustainability projects align with its main targets for 2030, 2040, and 2050, focusing on creating more value while consuming fewer resources and enhancing lives to generate lasting benefits.
Founded 113 years ago, Abdi Ibrahim remains committed to innovation and leadership, with a mission to leave a positive mark on the world. The company has shaped its sustainability strategy, “HEAL2050,” based on the European Green Deal, the UN’s 17 Sustainable Development Goals, and its internal risk and opportunity assessments. One of the three pillars of its strategy, “Improving the Future of the Ecosystem,” emphasizes minimizing environmental impact across all operations and contributing to the green transformation.
Focusing on reducing its environmental footprint, Abdi Ibrahim is determined to achieve carbon neutrality by 2030 and net zero emissions by 2050. The company has already transitioned to 100% renewable electricity at its Esenyurt Production Complex and headquarters, preventing 29,146 tons of CO₂e greenhouse gas emissions. In 2020, Abdi Ibrahim joined the Business Plastics Initiative, launched in partnership with Global Compact Turkey, the Sustainable Development Association of Turkey, and TÜSİAD, committing to reducing 17 tons of plastic waste. By 2023, the company surpassed its goal, cutting plastic waste by 127 tons and saving 204 tons of water.
Improving the Future of People and Business
Under the “Improving the Future of People” pillar, Abdi Ibrahim develops impactful projects that enhance the well-being of all stakeholders. As a leader in pharmaceutical employment, the company prioritizes talent management. Through the Abdi Ibrahim Academy, employees received an average of 26 hours of training in 2023. In social responsibility, the Abdi Ibrahim Foundation has provided shelter to children undergoing cancer treatment and their families through its “House of Kindness” initiative. Additionally, the company has launched high-impact educational and social innovation programs, including “Social Innovation in Healthcare,” “Raising Science Awareness Among Youth,” and “Corporate Volunteer Projects.”
With a vision of producing biotechnological products domestically from cell cultivation, Abdi Ibrahim continues to invest in research and innovation under the “Improving the Future of Business” pillar. In 2023, the company invested $125 million and allocated 320 million TL to R&D. Its responsible procurement strategy has increased the share of local suppliers to 74%. Furthermore, projects like the Sterile Ophthalmology & Sterile Inhalation Facility contribute significant value to the industry.
Commitment to a Net Zero Future by 2050
Dr. M. Oğuzcan Bülbül, Group Head of Human Resources, Corporate Communications, and Sustainability at Abdi Ibrahim, shared insights into the report: “By accelerating our sustainability efforts in line with global developments, we have implemented our HEAL2050 strategy. This vision aims to reduce environmental impact while creating social benefits. Transitioning to 100% renewable electricity at our headquarters and Esenyurt Production Complex was a key step toward lowering our carbon footprint. We are committed to achieving carbon neutrality by 2030 and net zero emissions by 2050. Since 2020, we have participated in the Carbon Disclosure Project (CDP) to transparently report our sustainability performance on international platforms. In 2023, we became the first Turkish pharmaceutical company to be included in the CDP Climate Change Program A List, marking a significant global achievement.
We are advancing our HEAL2050 goals with ambitious projects and fostering continuous learning among our employees and stakeholders. Our initiatives address climate change, energy and water conservation, waste management, operational efficiency, gender equality, and equal opportunities in education and healthcare. Through scientific, educational, and sports programs, we strive to make a positive social impact. Moving forward, we will publish our sustainability reports annually, providing public insights into our long-term sustainability roadmap. The initiatives outlined in our 7th Sustainability Report reflect our unwavering commitment to a more sustainable future.”
